Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Adverse Event Electronic Reporting Delayed To Complete Portal Roll-Out

This article was originally published in The Pink Sheet Daily

Executive Summary

Because some submitters will not have enough time to register for new electronic submission system, FDA will continue accepting paper post-marketing safety reports a little longer.

You may also be interested in...



FDA Adverse Event Reporting Reg Offers Few Exceptions

Companies must submit post-market safety reports electronically beginning in June 2015; waivers will be allowed, but they would only be temporary.

Adverse Event Rule Would Require e-Conversion Of 20 Percent Of Submissions

FDA's proposed rule to require electronic submission of adverse event information would mandate a switch that industry already seems to be making rapidly

Patient-Focused Drug Development, Complex Trial Design May Not Get More Funding In PDUFA VII

US FDA proposed increasing staffing and resources for both programs during the next user fee program cycle, but industry representatives did not believe it necessary.

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel